Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Also see our Top Picks for green tea supplements and drinks
Allergic reactions: Rare but requires vigilance
When you inject something, what's in the vial matters more than what's on the label
Jun 07, 2026, 17:30 ET CagriSema, a once-weekly investigational treatment that combines a novel amylin analog with a GLP-1 receptor agonist (RA), achieved significant reductions in HbA 1c and bodyweight versus comparators across three phase 3 trials in adults with type 2 diabetes (T2D) 1-3 Data from the REIMAGINE clinical development program, a series of phase 3 trials evaluating once-weekly CagriSema in adults with T2D across various stages of their disease, were presented at an ADA symposium 1-3 Novo Nordisk continues to demonstrate pioneering leadership and scientific innovation through advancing diabetes research PLAINSBORO, N.J
US$ 28.15
US$ 20.56
US$ 22.01
